Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial -

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet
Specialities: Cancers | Respiratory disorders
Summary
In Japanese patients with NSCLC and ≤1 prior chemotherapy regimen, alectinib 300mg BD was associated with longer progression-free survival than crizotinib 250mg BD (not reached [95% CI 20.3–not estimated] vs 10.2 months [8.2-12.0]; HR 0.34 [99.7% CI 0.17-0.71], p<0.0001).
UKMi comment
Alectinib, a highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), is licensed in the UK for the treatment of adults with ALK-positive advanced NSCLC previously treated with crizotinib. Although these results provide the first head-to-head comparison of alectinib and crizotinib, the dose of alectinib used in the study is lower than that currently licensed in countries other than Japan. The ongoing ALEX study is evaluating the dose licensed in the UK (see link below for further information).
Related links: Comment Ongoing study (clinicaltrials.gov)